A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 2, 2010, Pages 162-167

  Crawford, E D ^a   Black, L ^b   Eaddy, M ^c   Kruep, E J ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b GLAXOSMITHKLINE   (United States)

^c XCENDA   (United States)

Author keywords

Cost; Economic burden; Treatment; Watchful waiting

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; CORTICOSTEROID; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; KETOCONAZOLE;

ADULT; ARTICLE; CANCER PREVENTION; CANCER SURGERY; CANCER THERAPY; DATA BASE; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; WATCHFUL WAITING;

ADULT; AGED; COST OF ILLNESS; DATABASES, FACTUAL; HEALTH CARE COSTS; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77952541844     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.63     Document Type: Article

References (24)

1. American Cancer Society. Cancer Facts & Figures 2007. American Cancer Society: Atlanta, 2007.
2. American Cancer Society (ACS). Cancer Facts & Figures: 2008. Available at http://www.cancer.org/downloads/STT/2008CA FFfinalsecuredpdf; accessed March 2008.
3. National Cancer Institute (NCI). Cancer Trends Progress Report-2007 Update. Available at http://progressreport.cancer.gov; accessed March 2008.
4. Chodak G. Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 2006;8: S3-S8.
5. Johansson JE, Holmber L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 1997;277:467-471. (Pubitemid 27074330)
6. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004;22:3524-3530.
7. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004;171:2250-2254. (Pubitemid 38625445)
8. International Classification of Diseases. Ninth Revision, Clinical Modification (ICD-9-CM). Centers for Disease Control and Prevention: Hyattsville, MD, 1979.
9. Mag Mutual. Physician's Fee and Coding Guide 2008. MAG Mutual Healthcare Solutions, Inc: Atlanta, GA, USA
10. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 1999;88:1122-1130.
11. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-1984. (Pubitemid 40638368)
12. National Comprehensive Cancer Network and American Cancer Society, Prostate Cancer. Treatment Guidelines for Patients, Version VI, October 2007.
13. Anastasiadis AG, Salomon L, Katz R, Hoznek A, Chopin D, Abbou CC. Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology 2003;62:292-297.
14. Cohn JH, El-Galley R. Radical prostatectomy in a community practice. J Urol 2002;167:224-228.
15. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005;23:8146-8151; review.
16. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-2101. (Pubitemid 40617061)
17. Wallace, M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 2003;30:3003-3309.
18. Bailey DE, Wallace M. Critical review: is watchful waiting a viable management option for older men with prostate cancer? Am J Men's Health 2007;1:18-28.
19. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
20. Musquera M, Fleshner NE, Finelli A, Zlotta AR. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alphareductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008;8:1073-1079.
21. Andriole GL. Headline results of the REDUCE trial: the effect of dutasteride on prostate cancer risk reduction. Presented at: American Urological Association 2009 Annual Meeting; April 25-30, 2009; Chicago, IL. http://webcasts.prous.com/AUA2009/html/1-en/template.aspx?section= 20&idl= 7632&eid= 212; accessed July 24, 2009.
22. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40(Suppl 8): IV104-117.
23. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
24. Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 2007;89:207-211.